News & Updates

Show Multimedia Only

High remission rates in FLT3-ITD AML with quizartinib/omacetaxine combo

12 May 2026 by

Researchers from the University of Hong Kong found that therapy with the synergistic combination of quizartinib and omacetaxine mepesuccinate (QUIZOM) in acute myeloid leukaemia (AML) patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations produced high rates of composite complete remission (CRc), allowing more AML patients to be bridged to allogeneic haematopoietic stem cell transplantation (HSCT).

High remission rates in FLT3-ITD AML with quizartinib/omacetaxine combo

12 May 2026

Nitrofurantoin prevails in antibiotic showdown for uncomplicated UTI in women

11 May 2026 by

Nitrofurantoin performs better than single-dose fosfomycin in the treatment of uncomplicated urinary tract infections (UTIs) in women in the primary care setting, according to the SCOUT trial.

Nitrofurantoin prevails in antibiotic showdown for uncomplicated UTI in women

11 May 2026

Cancer patients at risk of heart disease death after surgery

11 May 2026

Patients who underwent primary cancer site surgery are at greater risk of death from heart disease than the general population, reports a US study.

Cancer patients at risk of heart disease death after surgery

11 May 2026

CtDNA testing predicts recurrence, enables personalized management in MIBC

11 May 2026 by

Circulating tumour DNA (ctDNA) testing after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) may inform patients with muscle-invasive bladder cancer (MIBC) of their risk for recurrence and allows personalized postoperative management in MIBC, results of the TOMBOLA trial have shown.

CtDNA testing predicts recurrence, enables personalized management in MIBC

11 May 2026

Immunotherapy improves survival in ES-SCLC in first-line setting

11 May 2026

First-line treatment with immune checkpoint inhibitors (ICIs) is safe and effective in patients with extended stage (ES) small-cell lung cancer (SCLC), but its use as second-line agent is not recommended, according to a study.

Immunotherapy improves survival in ES-SCLC in first-line setting

11 May 2026

Tebentafusp a ray of hope in rare eye cancer

11 May 2026 by

The 5-year data from the phase III IMCgp100-202 study demonstrate durable, long-term overall survival (OS) benefit with the novel agent tebentafusp—a first-in-class, bispecific, soluble T-cell receptor (TCR) therapeutic—in individuals with previously untreated metastatic uveal melanoma (UM).

Tebentafusp a ray of hope in rare eye cancer

11 May 2026

Depression common during the peripartum period

11 May 2026

Major depressive disorder is prevalent during the entire peripartum period, with the highest prevalence observed 2 weeks following childbirth, as shown in a study.

Depression common during the peripartum period

11 May 2026

Original New Drug Application Approvals by US FDA (16-30 April 2026)

11 May 2026

New drug applications approved by US FDA as of 16-30 April 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 April 2026)

11 May 2026

Excessive IPFD ups risk of pancreatic diseases

10 May 2026 by

Excessive intrahepatic fat deposition (IPFD) appears to contribute to an increased risk of major pancreatic disease, suggests a recent study, noting the potential benefits of IPFD reduction in preventing pancreatitis and pancreatic cancer.

Excessive IPFD ups risk of pancreatic diseases

10 May 2026

Paediatric AKI survivors at elevated risk of late adverse outcomes

10 May 2026

Acute kidney injury (AKI) in children is associated with increased long-term risks of adverse outcomes such as chronic kidney disease (CKD) and mortality, according to a systematic review and meta-analysis.

Paediatric AKI survivors at elevated risk of late adverse outcomes

10 May 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

High remission rates in FLT3-ITD AML with quizartinib/omacetaxine combo

High remission rates in FLT3-ITD AML with quizartinib/omacetaxine combo

Nitrofurantoin prevails in antibiotic showdown for uncomplicated UTI in women

Nitrofurantoin prevails in antibiotic showdown for uncomplicated UTI in women

Cancer patients at risk of heart disease death after surgery

Cancer patients at risk of heart disease death after surgery

CtDNA testing predicts recurrence, enables personalized management in MIBC

CtDNA testing predicts recurrence, enables personalized management in MIBC

Immunotherapy improves survival in ES-SCLC in first-line setting

Immunotherapy improves survival in ES-SCLC in first-line setting

Tebentafusp a ray of hope in rare eye cancer

Tebentafusp a ray of hope in rare eye cancer

Depression common during the peripartum period

Depression common during the peripartum period

Original New Drug Application Approvals by US FDA (16-30 April 2026)

Original New Drug Application Approvals by US FDA (16-30 April 2026)

Excessive IPFD ups risk of pancreatic diseases

Excessive IPFD ups risk of pancreatic diseases

Paediatric AKI survivors at elevated risk of late adverse outcomes

Paediatric AKI survivors at elevated risk of late adverse outcomes